Search Results

Bio-Thera Solutions (688177:SH) and global specialty, generic and consumer healthcare medicines company STADA Arzneimittel AG have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® (golimumab).

NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the first product to be distributed under its recently formed partnership with STADA Arzneimittel AG (“STADA”), a European leader in consumer health.

NEXGEL, Inc. announced a partnership with STADA Arzneimittel AG, a European leader in consumer health, to distribute and commercialize consumer health OTC products in North America in 2024.

Alvotech and STADA are strengthening their existing strategic alliance for high-quality, cost-effective biosimilars by extending their partnership to cover AVT03, a clinical-stage biosimilar candidate referencing the Prolia®/Xgeva® medicines for osteoporosis and cancer-related bone loss respectively.

Stada announced Tuesday it has secured European rights from Alvotech to a clinical-stage biosimilar of Amgen’s blockbuster bone drugs Prolia and Xgeva.

Amid strong performance in the first half of 2023, Stada Arzneimittel’s private equity owners are considering a potential sale, though there are still no definite plans, according to CEO Peter Goldschmidt.

Partners STADA and Alvotech announced that the European Commission issued a marketing authorization for Uzpruvo®, a biosimilar candidate to Stelara®.

Partners STADA and Alvotech announced that the Committee for Medicinal Products for Human Use within the European Medicines Agency has adopted a positive opinion for Uzpruvo, a biosimilar candidate to Stelara®.

Exelixis, Inc. (Nasdaq: EXEL) today announced it has successfully defended European Patent number EP2593090 (c-MET Modulator Pharmaceutical Compositions) against three opponents, STADA Arzneimittel AG, Teva Pharmaceutical Industries Ltd., and Generics (U.K.) Ltd. in a hearing before the Opposition Division of the European Patent Office (EPO).